For estrogen receptor-positive breast carcinoma, ctDNA surveillance can identify acquired ESR1 mutations associated with endocrine therapy resistance, with FDA approval of the Guardant360 CDx test specifically for detecting ESR1 mutations to guide elacestrant treatment decisions [7]. The gene discussed is ESR1; the disease is breast carcinoma.